Mitochondria are key mediators of the cardioprotective signal and the mitochondrial ATP-sensitive K ϩ channel (mitoK ATP ) plays a crucial role in originating and transmitting that signal. Recently, protein kinase C ⑀ (PKC) has been identified as a component of the mitoK ATP signaling cascade. We hypothesized that PKC and mitoK ATP interact directly to form functional signaling modules in the inner mitochondria membrane. To examine this possibility, we studied K ϩ flux in liposomes containing partially purified mitoK ATP . The reconstituted proteins were obtained after detergent extraction of isolated mitochondria, 200-fold purification by ion exchange chromatography, and reconstitution into lipid vesicles. Immunoblot analysis revealed the presence of PKC in the reconstitutively active fraction. Addition of the PKC activators 12-phorbol 13-myristate acetate, hydrogen peroxide, and the specific PKC peptide agonist, RACK, each activated mitoK ATP -dependent K ϩ flux in the reconstituted system. This effect of PKC was prevented by chelerythrine, by the specific PKC peptide antagonist, V 1-2 , and by the specific mitoK ATP inhibitor 5-hydroxydecanoate. In addition, the activating effect of PKC agonists was reversed by exogenous protein phosphatase 2A. These results demonstrate persistent, functional association of mitochondrial PKC and mitoK ATP . (Circ Res. 2006;99:878-883.)
I schemic preconditioning is a powerful method for reducing ischemia/reperfusion injury in the heart, and it is widely considered that opening of the mitochondrial ATP-sensitive K ϩ channel (mitoK ATP ) plays a crucial role in this process. Cardioprotection by ischemic preconditioning can be mimicked by administering G i -coupled surface receptor agonists, such as bradykinin, and there has been progress in understanding the mechanisms by which receptor agonists open mitoK ATP . Recent findings by Oldenburg et al 1 led those authors to conclude that protein kinase G (PKG) is the terminal cytosolic kinase in this pathway, with the next step being opening of mitoK ATP . We then showed that mitoK ATP opening could be induced by adding exogenous PKGϩcGMP to isolated heart mitochondria. 2 We also showed that an endogenous, mitochondrial protein kinase C ⑀ (PKC) is an obligatory intermediate between PKG and mitoK ATP in this process. 2 These findings raise the question of PKC localization in mitochondria. It seemed unlikely that PKC would be required to probe the entire inner membrane surface area to find its substrate, given that mitoK ATP is a very low abundance protein. Accordingly, we hypothesized that these 2 proteins are joined in a complex.
To examine this possibility, we studied K ϩ flux in proteoliposomes containing partially purified mitoK ATP . We found that the reconstitutively active fraction contains PKC, as revealed by immunoblot. We observed that addition of the PKC activators, 12-phorbol 13-myristate acetate (PMA) and H 2 O 2 , and the specific PKC peptide agonist, RACK, reversed ATP inhibition of K ϩ flux in proteoliposomes reconstituted with mitoK ATP . PKC-dependent mitoK ATP opening was inhibited by the PKC inhibitor chelerythrine, by the specific PKC peptide antagonist, V 1-2 , and by the mitoK ATP inhibitor 5-hydroxydecanoate (5-HD). Moreover, the activating effect of PKC agonists was reversed by exogenous protein phosphatase 2A (PP2A). We conclude that activation of PKC leads to phosphorylation of mitoK ATP , that PKC is constitutively expressed in mitochondria, and that there is a functional association of mitochondrial PKC and mitoK ATP .
Materials and Methods

Chemicals and Reagents
The PKC-specific peptides V 1-2 (EAVSLKPT) and RACK (HDAPIGYD) were synthesized with stated purity Ͼ98% by EZBiolab (Westfield, Ind.), according to the amino acid sequences described by Dorn et al. 3 The PKC inhibitor peptide control, a scrambled peptide to V 1-2 (LSETKPAV), was from Calbiochem (San Diego, Calif.), and the anti-PKC antibody (clone 21) was from BD Biosciences (San Jose, Calif). PP2A was from Calbiochem (San Diego, Calif) and exhibited a specific activity of 1800 U/mg as supplied. BODIPY-FL-glibenclamide and the potassium binding fluorescent indicator potassium-binding benzofuran isophthalate (PBFI) were from Molecular Probes (Eugene, Ore). All other chemicals were from Sigma-Aldrich Chemical Co (St. Louis, Mo).
Isolation of Mitochondria and Fractionation of Mitochondrial Proteins
Rat liver mitochondria (RLM) were used for these studies. RLM possess the same PKC -dependent mitoK ATP opening as heart and brain mitochondria, 2 and the yield of RLM is much greater because of the greater amount of starting material. Mitochondria were isolated and purified on a Percoll gradient exactly as previously described. 2 The mitochondrial protein extraction and fractionation followed previously described protocols, 4,5 with modifications. Mitochondria were solubilized at a protein concentration of 5 mg/mL in column buffer containing Triton X-100 (46.5 mmol/L), EDTA (1 mmol/L), ␤-mercaptoethanol (13 mmol/L), and Tris (50 mmol/L), pH 7.2 adjusted by HCl. Approximately 600 mg of the extracted proteins was loaded on 10 mL of DEAE-cellulose ion exchange column at a flow rate of 0.4 mL/min. The loading of the first 300 mg of protein was followed by washing the column with 2 column bed volumes of column buffer, containing Triton X-100 (3 mmol/L), EDTA (1 mmol/L), ␤-mercaptoethanol (13 mmol/L), and Tris (50 mmol/L), pH 7.2 adjusted by HCl. The remaining 300 mg of the protein was loaded and the column was washed for 10 hours at a flow rate of 0.1 mL/min with column buffer containing 100 mmol/L KCl. The column was further washed sequentially with column buffer containing 150, 250, and 500 mmol/L KCl, at least 2 column bed volumes each, at a flow rate of 0.4 mL/min. MitoK ATP activity was found in the 250 mmol/L KCl fraction, 4 referred to here as the "active fraction".
Reconstitution and K ؉ Flux Measurements
Reconstitution of mitoK ATP activity into PBFI-loaded liposomes was performed as described previously. 5 Intraliposomal buffer contained PBFI (150 mol/L) and tetraethylammonium (TEA ϩ ) salts of SO 4 (100 mmol/L), EDTA (1 mmol/L), and Hepes (25 mmol/L), pH 6.8. Kinetic studies were performed in external medium containing MgCl 2 (0.5 mmol/L) and K ϩ salts of SO 4 (80 mmol/L), and Hepes (25 mmol/L), pH 7.2. Electrophoretic K ϩ flux through mitoK ATP was initiated by FCCP (0.25 mol/L), which provides charge compensation. Fluorescence changes of the K ϩ -sensitive probe PBFI were monitored using an SLM/Aminco 8000C fluorescence spectrophotometer ( ex / em ϭ345/485 nm), with fluorescence signals calibrated to K ϩ flux as previously described. 6 Control experiments were performed using an ion exchange chromatography fraction that did not exhibit specific mitoK ATP activity. None of the tested compounds had any effect on these K ϩ fluxes (data not shown). As is usual, we observed K ϩ flux in the presence of ATP (see Figure 3 ), which was about twice as high as background diffusive K ϩ flux (data not shown). As this level of flux is only observed in the fraction containing mitoK ATP activity, we speculate that it is attributable to insertion of incomplete and unregulatable mitoK ATP channels.
Western Blot Studies
Proteins from RLM (85 g) and from the active fraction (3 g to 6 g) were precipitated using methanol-chloroform ref 7 (with minor modifications) and resolved on 10% SDS-PAGE gels. Proteins separated on the gels were silver stained (Silver Stain Plus, Bio-Rad) or transferred onto polyvinylidene fluoride (PVDF) membranes (Immobilon-P transfer membrane, Millipore). After blocking with gelatin (25 g/L) in Tris-buffered saline, the PVDF mebranes were exposed to anti-PKC antibody in a 1:500 dilution followed by alkaline phosphatase-conjugated secondary antibody (Immunoblot Assay kit goat anti-mouse IgG alkaline phosphatase, Bio-Rad). A colorimetric assay was used to visualize antigen-antibody reactions following manufacturer's instructions.
BODIPY-FL-glibenclamide Labeling of the DEAE-Cellulose Fractions
Aliquots of each fraction eluted from the DEAE-cellulose column were incubated with BODIPY-FL-glibenclamide (100 nmol/L) in the presence or absence of unlabeled glibenclamide (1 mol/L) for 10 minutes at room temperature. Adding a 10-fold excess of unlabeled glibenclamide is not expected to affect nonspecific (low-affinity) labeling, but it is expected to compete at specific (high-affinity) binding sites and to lower BODIPY-FL-glibenclamide labeling at those sites at least 10-fold. The samples were transferred to Costar 24-well ultra-low attachment cluster plates and UV-irradiated for 6 minutes on ice in a UVP CL-1000 Ultraviolet Crosslinker at 200 mJ/cm 2 . To remove unbound BODIPY-FL-glibenclamide, the samples were precipitated using trichloroacetic acid and sodium deoxycholate followed by two 5-minute 400 L acetone washes. The samples were dried and resuspended in TEA-EDTA (1 mmol/L), SDS (17.3 mmol/L), and Tris-HCl (50 mmol/L), pH 7.2. The fluorescence emission spectrum for each sample from 495 to 565 nm was collected using an SLM/Aminco 8000C spectrofluorometer, and analyzed for BODIPY-FL-glibenclamide fluorescence ( ex / em ϭ493/ 515 nm). For each fraction, the 2 emission spectra, with and without unlabeled glibenclamide, were integrated between 510 and 550 nm. Subtracting the former from the latter and expressing the difference as a ratio over the unlabeled glibenclamide control corrected for small differences in the protein concentration.
Results
Copurification of Mitochondrial PKC With MitoK ATP
Our previous finding that activation of PKC causes mitoK ATP opening in heart, liver, and brain mitochondria 2 indicated that PKC is constitutively localized in mitochondria. This was confirmed by immunodetection, as shown in Figure 1A . A clear signal at Ϸ90 kDa was observed in RLM (lane 1), which persisted after Percoll purification (lane 2). The abundance of mitoK ATP is very low, and efficient regulation would seem to require colocalization of mitoK ATP and PKC. Accordingly, we investigated whether PKC and mitoK ATP copurify following detergent extraction and subsequent fractionation using ion exchange column chromatography. The immunoblot shown in lane 3 of Figure 1A was performed on the reconstitutively active fraction containing mitoK ATP and demonstrates the presence of PKC in this fraction. None of the other fractions from the ion exchange column exhibited a positive reaction with anti-PKC antibodies (not shown). Essentially identical results were obtained using rat heart mitochondria (nϭ4, data not shown). Figure 1B contains an SDS-PAGE gel of the reconstitutively active fraction. Numerous bands were observed on silver staining, as is typical of rat liver mitochondria. Figure  1B shows the band pattern we currently find in the fraction used for reconstitution experiments. The band pattern of the reconstitutively active fraction is similar but not identical to the patterns shown previously by Paucek et al, 4 who used RLM, and by Bajgar et al, 5 who used rat brain mitochondria. We attribute the differences in the observed protein band pattern to the differences in selected tissue and staining procedure, to the modifications in the protein fractionation protocol, which included broader salt step gradient, to a different flow rate of the ion exchange column, and to the fact that a much smaller aliquot was used for the gel in Figure 1B , so that minor bands were emphasized (see Materials and Methods).
To further confirm colocalization of PKC and mi-toK ATP , we performed BODIPY-FL-glibenclamide labeling experiments 5 on the column fractions, with the results shown in Figure 2 . It can be seen that the fraction containing PKC ("250" fraction) also exhibited specific labeling with BODIPY-FL-glibenclamide. High affinity glibenclamide binding is one of the ascribed properties of mitoK ATP and these data provide strong evidence that PKC copurifies with mitoK ATP . We shall refer to this pool of PKC as mitoPKC.
Functional Association of MitoPKC With MitoK ATP
We next performed experiments to examine whether the colocalized mitoPKC and mitoK ATP retained a functional association through detergent extraction, partial purification and reconstitution in liposomes. If this were so, the activation of endogenous PKC should reverse ATP inhibition of K ϩ flux in proteoliposomes as it does in isolated mitochondria. 2 Indeed, this was found to be the case, as shown in Figure 3 . In these experiments, K ϩ flux in the open state (Figure 3 , no ATP) was inhibited by ATP (Figure 3 , ATP), as previously shown. 4 Addition of the phorbol ester PMA reversed ATP inhibition so that K ϩ flux returned to the control value ( Figure  3A, ATPϩPMA) . Addition of the inactive 4␣ analogue of PMA did not reverse ATP inhibition ( Figure 3A , ATP ϩ4␣PMA). The PKC inhibitor, chelerythrine, blocked the activating effect of PMA ( Figure 3A, ATPϩchelϩPMA) .
In a similar experiment, addition of the PKC peptide agonist RACK reversed the ATP inhibition ( Figure 3B , 
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ATPϩRACK). Addition of the PKC-specific peptide antagonist V 1-2 blocked the activating effect of RACK ( Figure 3B , ATPϩV 1-2 ϩRACK). The scrambled peptide analog to V 1-2 did not block the effect of RACK ( Figure  3B , ATPϩV 1-2-S ϩRACK) or the effect of PMA (data not shown). Ten-fold higher concentrations of the scrambled peptide analog were also without an effect (data not shown). The results obtained from 3 or more independent reconstitutions examining the effects on K ϩ flux of various PKC agonists and antagonists are summarized in Figure 4A . The addition of the general PKC activators PMA and H 2 O 2 , as well as the specific PKC peptide agonist RACK, increased K ϩ fluxes in the presence of ATP nearly to the level of control. MitoK ATP opening by PKC activators was inhibited by both chelerythrine and the PKC-specific peptide antagonist V 1-2 . MitoK ATP opening by PKC activators was also inhibited by the mitoK ATP inhibitor 5-HD. These results show that PKC and mitoK ATP copurified and remained functionally and physically associated through purification and reconstitution.
We performed analogous experiments using the cardioprotective pharmacological opener diazoxide. 8 The results of 3 independent reconstitutions are summarized in Figure 4B . As shown previously, 9 ATP inhibition of K ϩ flux was reversed by diazoxide, and the diazoxide-opened channel was inhibited by 5-HD. An important point to note in Figure 4B is that the PKC antagonists, chelerythrine and V 1-2 , had no effect on the K ϩ flux induced by diazoxide. Additional control experiments were performed on the proteoliposomes, using the open state of mitoK ATP in the absence of ATP, which should be insensitive to regulation. Figure 4B shows that none of the tested compounds had any significant effect on the FCCPinduced K ϩ fluxes observed in the absence of ATP.
Reversal of PKC-Dependent MitoK ATP Opening By PP2A
Our results are consistent with a mitoPKC-dependent phosphorylation of mitoK ATP or an intermediate protein that activates mitoK ATP . The results in Figure 5 confirm that PKC-dependent mitoK ATP opening was mediated by a Ser/ Thr kinase by demonstrating its reversal with PP2A, a Ser/Thr protein phosphatase. These experiments were performed by adding PMA, chelerythrine, and PP2A sequentially at 10s intervals. PMA reversed ATP inhibition of K ϩ flux, as shown in Figure 3 . Addition of chelerythrine after PMA had no effect ( Figure 5, PMAϩchel) , showing that chererythrine cannot block the effect of PKC after phosphorylation has occurred. The subsequent addition of PP2A, 10 seconds before the addition of FCCP, reversed the activating effect of PMA ( Figure 5, PMAϩchelϩPP2A) . In the absence of PMA, PP2A had no effect on K ϩ flux ( Figure 5,  chelϩPP2A) , demonstrating that PP2A had no further effect Figure 3 . The concentrations of chelerythrine, V 1-2 and 5-HD were 50 nmol/L, 1 mol/L, and 0.5 mmol/L, respectively. The halfmaximal inhibition by V 1-2 was Ϸ0.3 mol/L (data not shown). The dataϮS.D. were obtained from 3 or more independent reconstitutions. ATP-sensitive K ϩ flux was calculated as a ratio of rates corrected for the flux in the presence of ATP (⌬J) and normalized for the maximal ATP-sensitive control rate (⌬J max ).
Figure 5.
Shown are traces reflecting electrophoretic K ϩ influx in proteoliposomes containing reconstituted mitoK ATP as monitored by PBFI fluorescence. The electrophoretic K ϩ influx was initiated by the addition of 250 nmol/L FCCP. Addition of 0.2 mmol/L ATP was followed by the addition of 50 nmol/L PMA and, after 10 seconds, the addition of 50 nmol/L chelerythrine (ATPϩPMAϩchel). The addition of 22 ng/mL exogenous PP2A following the addition of chelerythrine 10 seconds before the addition of FCCP reversed the effect of PMA (ATPϩPMAϩ chelϩPP2A). In the absence of PMA, chelerythrine and PP2A had no effect on the ATP-inhibited K ϩ flux (ATPϩchelϩPP2A).
on the ATP-inhibited K ϩ flux and implying that mitoK ATP as purified is not significantly phosphorylated.
Discussion
The remarkable outcome of these studies is that they show a persistent association of mitoPKC and mitoK ATP through detergent extraction, Ϸ200-fold purification by ion exchange chromatography, and reconstitution into proteoliposomes. Specific antibodies recognized PKC in the same ion exchange column fraction that contains mitoK ATP activity and BODIPY-FL-glibenclamide binding (Figure 1 and 2) . The amount of mitoPKC is small; the immunoblot in Figure 1A was obtained using 1/3 of the entire active fraction from 4 rat livers. These findings indicate that PKC is constitutively expressed in mitochondria and tightly bound to the inner mitochondrial membrane.
The PKC agonists PMA, H 2 O 2 , and RACK caused mitoK ATP opening in the presence of ATP, and this activation of mitoK ATP was blocked by chelerythrine, V 1-2 , and 5-HD (Figure 3 and 4 ). PKC-dependent mitoK ATP opening was reversed by the Ser/Thr protein phosphatase 2A ( Figure 5 ). These results support and extend previous studies showing that PKC-dependent signaling targets mitochondria 10, 11 and that PKC is a part of the mitoK ATP signaling cascade. 2, [12] [13] [14] Our data demonstrate a functional association between mi-toK ATP and PKC, and suggest their coexistence in a multiprotein signaling complex.
Mochly-Rosen and coworkers 15-17 generated a PKCspecific peptide agonist, RACK, that acts by regulating intramolecular binding, and a PKC-specific peptide antagonist, V 1-2 , that acts by preventing protein-protein interactions between PKC and its binding protein, called a RACK (receptor for activated C kinase). RACK was found to protect cardiac cells from ischemic damage, whereas V 1-2 caused a loss of protection. Based on those results, Murriel and Mochly-Rosen 11 concluded that PKC activation is necessary and sufficient to mediate cardioprotection from ischemic damage.
PKC requires anionic phospholipids for activity and is activated physiologically by 1 of 2 second messengers, diacylglycerol (DAG) or H 2 O 2 , or by phosphorylation. 18 The phospholipid requirement for most PKCs is usually met by phosphotidylserine; however cardiolipin, which is very abundant in mitochondria, enhances PKC activity three-to four-fold compared with phosphatidylserine. 19 To date, most, but not all, 20 PKCs have been found to be translocated from 1 location to another. Indeed, translocation, rather than functional consequence, has been used most commonly as the indicator of PKC activation. 18, 21 The mitoPKC described here is not translocated from location to location, but rather is tightly bound to inner membrane proteins and phospholipids. Nevertheless, our findings can readily be interpreted in the context of the model described by Ron and Mochly-Rosen. 15 In this model, inactive mitoPKC is bound to a RICK (receptor for inactive C kinase). Addition of RACK, DAG (or PMA), or H 2 O 2 causes conformational changes that expose the substrate domain on PKC and cause its binding to its RACK. This step corresponds to translocation from RICK to RACK, which may reside on the same binding protein, and is followed by phosphorylation of the PKC substrate. Addition of PMA or H 2 O 2 opens up 1 of the 2 zinc fingers in PKC. 22, 23 It has been suggested that H 2 O 2 activates PKC indirectly, via a protein tyrosine kinase (PTK), and indeed, this has been demonstrated in vitro by Konishi et al. 24 However, the latter work used 5 mmol/L H 2 O 2 , whereas our activation occurred with a K 1/2 of Ϸ0.5 mol/L. Moreover, mitoK ATP opening via PKC is insensitive to the PTK inhibitor genistein, 2 arguing against a role for PTK. Accordingly, we suggest that mitoPKC is activated directly by H 2 O 2 . Because all 3 agonists cause binding of activated PKC to its RACK, 17 the model predicts that the binding antagonist V 1-2 should block all 3 modes of PKC activation of mitoK ATP , 15 and this indeed was found to be the case in our experiments.
Our data indicate that there is a specific association between mitoK ATP and its regulatory kinase, mitoPKC, that persists through several steps of purification. Although a functional mitoK ATP -PKC association is demonstrated by this work, the question whether this reflects existence of a structural signaling complex must await identification of the molecular entities responsible for mitoK ATP activity.
